Literature DB >> 29132539

The diabetic heart utilizes ketone bodies as an energy source.

Yuji Mizuno1, Eisaku Harada2, Hitoshi Nakagawa3, Yoshinobu Morikawa4, Makoto Shono2, Fumihito Kugimiya2, Michihiro Yoshimura5, Hirofumi Yasue2.   

Abstract

BACKGROUND: Diabetic heart is characterized by failure of insulin to increase glucose uptake and increasingly relies on free fatty acids (FFAs) as a source of fuel in animal models. However, it is not well known how cardiac energy metabolism is altered in diabetic hearts in humans. We examined cardiac fuel metabolism in the diabetics as compared to non-diabetics who underwent cardiac catheterization for heart diseases.
MATERIAL AND METHODS: The study subjects comprised 81 patients (male 55, female 26, average age 63.0±10.0years) who underwent the cardiac catheterization for heart diseases. Thirty-six patients were diagnosed as diabetics (diabetic group) and 45 as non-diabetics (non-diabetic group). Blood samplings were done in both the aortic root (Ao) and coronary sinus (CS) simultaneously and the plasma levels of FFAs, glucose, lactate, pyruvate, total ketone bodies and β-hydroxybutyrate were measured and compared between the two groups.
RESULTS: The myocardial uptake of glucose, lactate and pyruvate were decreased, whereas those of total ketone bodies, β-hydroxybutyrate and acetoacetate were increased in the diabetics as compared to the non-diabetics. However, the myocardial uptakes of FFAs were not significantly increased in the diabetics as compared to the non-diabetics.
CONCLUSIONS: Cardiac uptakes of carbohydrate (glucose, lactate and pyruvate) were decreased, whereas those of total ketone bodies and β-hydroxybutyrate were increased in the diabetics as compared to the non-diabetics in humans. Ketone bodies therefore are utilized as an energy source partially replacing glucose in the human diabetic heart.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac metabolism; Diabetes mellitus; Fatty acids; Glucose; Ketone bodies

Mesh:

Substances:

Year:  2017        PMID: 29132539     DOI: 10.1016/j.metabol.2017.08.005

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  40 in total

Review 1.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

2.  Heart failure prevention with sodium-glucose cotransporter 2 inhibitors.

Authors:  Muhammad Shahzeb Khan; Javed Butler
Journal:  J Diabetes       Date:  2019-05-01       Impact factor: 4.006

3.  Why the diabetic heart is energy inefficient: a ketogenesis and ketolysis perspective.

Authors:  Paras Kumar Mishra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-09-17       Impact factor: 5.125

Review 4.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 5.  SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.

Authors:  Xiaodan Wang; Jingyu Ni; Rui Guo; Lan Li; Jing Su; Feng He; Guanwei Fan
Journal:  Heart Fail Rev       Date:  2021-03-12       Impact factor: 4.214

Review 6.  Ketone body metabolism in diabetic and non-diabetic heart failure.

Authors:  Ningjing Qian; Yaping Wang
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

Review 7.  Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.

Authors:  Dimitrios A Vrachatis; Konstantinos A Papathanasiou; Konstantinos E Iliodromitis; Sotiria G Giotaki; Charalampos Kossyvakis; Konstantinos Raisakis; Andreas Kaoukis; Vaia Lambadiari; Dimitrios Avramides; Bernhard Reimers; Giulio G Stefanini; Michael Cleman; Georgios Giannopoulos; Alexandra Lansky; Spyridon G Deftereos
Journal:  Drugs       Date:  2021-07-23       Impact factor: 9.546

8.  Association of beta-hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort.

Authors:  Jose L Flores-Guerrero; Berend Daan Westenbrink; Margery A Connelly; James D Otvos; Dion Groothof; Irina Shalaurova; Erwin Garcia; Gerjan Navis; Rudolf A de Boer; Stephan J L Bakker; Robin P F Dullaart
Journal:  Eur J Clin Invest       Date:  2020-12-18       Impact factor: 4.686

Review 9.  Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy.

Authors:  Linda R Peterson; Robert J Gropler
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

10.  β-Hydroxybutyrate inhibits histone deacetylase 3 to promote claudin-5 generation and attenuate cardiac microvascular hyperpermeability in diabetes.

Authors:  Bin Li; Yijin Yu; Kun Liu; Yuping Zhang; Qi Geng; Feng Zhang; Yanning Li; Jinsheng Qi
Journal:  Diabetologia       Date:  2020-10-27       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.